Drug lookup
Drug reference

Insulin Lispro

Rapid-acting insulin analogue · Antidiabetic

START
SC 0–15 min before meals; individualised by carb ratio/correction factor
TYPICAL MAX
No fixed ceiling — titrate to prandial glucose
STOP IF
Hypoglycaemia (treat first)
WATCH
Pre/post-meal glucose, hypoglycaemia (esp. renal impairment, missed meals), injection technique, correct strength
CDSCO approvedATC A10AB04
Renal dose adjustmenteGFR mL/min/1.73m²
FULLUsual titration to glucose60CAUTIONReduced requirement — titrate down15REDUCEMarkedly reduced…90

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours
15minONSET1hPEAK1h4hDURATION
ONSET
15min · prandial onset
PEAK
1h · peak
1h · effect t½
DURATION
4h · prandial duration
EXCRETION
Enzymatic degradation (hepatic/renal)
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Acceptable in pregnancy when prandial insulin needed — commonly used; titrate to targets
FDA category + note
Top interactionssee all 12
  • CinoxacinSevereDatabaseDDInter
  • CiprofloxacinSevereDatabaseDDInter
  • DelafloxacinSevereDatabaseDDInter
  • EnoxacinSevereDatabaseDDInter
Available in India

7 branded formulations and 8 fixed-dose combinations. Look up specific brands in the Drugs workspace.

Mechanism

Recombinant insulin analogue (Lys-B28, Pro-B29 reversal) reducing self-association → faster SC absorption and rapid, short prandial insulin-receptor agonism; mimics physiological mealtime insulin.

Indications

Type 1 and type 2 diabetes mellitus — prandial (bolus) coverageInsulin pump (CSII) therapy

Dosing

Adult
SC immediately before (0–15 min) or just after meals; individualised by carbohydrate counting/correction. Also CSII and (lispro) IV in specialist settings. U-100 and U-200 available.
Pediatric
Weight/meal-based, individualised (specialist).
Renal adjustment
Reduced insulin requirement in renal impairment — titrate down.
Hepatic adjustment
Variable requirement; titrate to glucose.
Geriatric
Conservative targets; hypoglycaemia risk.
Max dose
No fixed ceiling — titrated to prandial glucose

Pharmacokinetics

Onset
~15 min
Peak effect
~30–90 min
Duration
~3–5 h
Half-life
~1 h (SC effect)
Bioavailability
SC
Protein binding
Low
Metabolism
Hepatic/renal insulin-degrading enzyme
Excretion
Renal degradation

Contraindications

  • Hypoglycaemia
  • Hypersensitivity to insulin lispro/excipients

Side effects

Common
HypoglycaemiaWeight gainInjection-site lipohypertrophy/reactionsTransient visual changes on initiation
Serious
  • Severe hypoglycaemia (coma/seizure)
  • Severe hypokalaemia
  • Severe hypersensitivity/anaphylaxis (rare)

Pregnancy & lactation

Pregnancy

Acceptable in pregnancy when prandial insulin needed — commonly used; titrate to targets

Lactation

Compatible — not orally bioavailable to infant; adjust maternal dose

Drug interactions

Cinoxacin
Severe
Database

Drug interaction classified as: antagonism

Source: DDInter

Ciprofloxacin
Severe
Database

Drug interaction classified as: antagonism.

Source: DDInter

Delafloxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Enoxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Gatifloxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Gemifloxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Grepafloxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Levofloxacin
Severe
Database

.

Source: DDInter

Lomefloxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Moxifloxacin
Severe
Database

.

Source: DDInter

Nalidixic Acid
Severe
Database

Clinical effect not specified

Source: DDInter

Norfloxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Other Rapid-acting insulin analogue drugs

Ask House about Insulin Lispro

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-19 · House clinical team·Cockpit curated: 2026-05-19